Most Profitable NASDAQ Biotechnology Companies

Net Income
Net IncomeEfficiencyMarket RiskExp Return
1AZN AstraZeneca PLC ADR
8.69 B
 0.16 
 1.15 
 0.19 
2GMAB Genmab AS
7.84 B
(0.01)
 2.80 
(0.03)
3SNY Sanofi ADR
5.5 B
 0.15 
 1.37 
 0.21 
4REGN Regeneron Pharmaceuticals
4.41 B
(0.08)
 2.07 
(0.16)
5ROIV Roivant Sciences
4.23 B
(0.09)
 1.91 
(0.18)
6AMGN Amgen Inc
4.09 B
 0.18 
 1.52 
 0.27 
7INBX Inhibrx
1.69 B
(0.01)
 3.43 
(0.02)
8BIIB Biogen Inc
1.63 B
(0.06)
 1.74 
(0.11)
9RPRX Royalty Pharma Plc
1.33 B
 0.19 
 2.06 
 0.38 
10UTHR United Therapeutics
1.2 B
(0.10)
 2.30 
(0.23)
11ARGX argenx NV ADR
804.13 M
(0.06)
 1.72 
(0.10)
12AGIO Agios Pharm
673.73 M
(0.05)
 2.55 
(0.12)
13JAZZ Jazz Pharmaceuticals PLC
560.12 M
 0.02 
 1.79 
 0.04 
14EXEL Exelixis
521.27 M
 0.09 
 2.41 
 0.21 
15GILD Gilead Sciences
480 M
 0.18 
 1.62 
 0.30 
16HALO Halozyme Therapeutics
444.09 M
 0.34 
 1.45 
 0.49 
17BMRN Biomarin Pharmaceutical
426.86 M
 0.09 
 1.65 
 0.15 
18MEDP Medpace Holdings
404.39 M
(0.05)
 2.02 
(0.10)
19ALKS Alkermes Plc
367.07 M
 0.12 
 1.94 
 0.24 
20NBIX Neurocrine Biosciences
341.3 M
(0.10)
 2.83 
(0.29)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors. Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.